Pharmacogenomics aims to develop rational means to optimize drug therapy with respect to the patient’s genotype, ensuring maximum drug efficiency with minimal adverse effects. A deeper understanding of different groups and populations improves pharmacovigilance, clinical trials, and the real-world therapeutic efficiency of drugs.
You may also be interested in:
Fact Sheet
Aggregate Safety Reports
PRA Health Sciences (PRA) is dedicated to ensuring quality Aggregate Safety Reports are delivered to our sponsor and MAH partners. Our experienced…
Webcast
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…
resource
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…